Humacyte (HUMA) Stock Statistics & Valuation Metrics

Humacyte has a market cap or net worth of $373.84M. The enterprise value is $156.19M.

Humacyte has 155,118,820 shares outstanding. The number of shares has decreased by -2.65% in one year.

Humacyte’s return on equity (ROE) is 0.00 and return on invested capital (ROIC) is ―.

The current PE Ratio of Humacyte is 0.00. Humacyte’s PEG ratio is >-0.01.

In the last 12 months, Humacyte had revenue of 0.00 and earned 0.00 in profits. Earnings per share was -1.26.

In the last 12 months, operating cash flow was -98.12M and capital expenditures -1.57M, giving a free cash flow of -99.69M billion.

Humacyte pays an annual dividend of ―, resulting in a dividend yield of ―

Humacyte upcoming earnings date is Aug 19, 2025, TBA Not Confirmed.

Humacyte as a current ratio of 2.40, with Debt / Equity ratio of -31.40%

In the past 12 months, Humacyte has paid 0.00 in taxes.

Humacyte EV to EBITDA ratio is -4.98, with an EV/FCF ratio of -5.72.

Humacyte has $44.94M in cash and marketable securities with $16.54M in debt, giving a net cash position of -$28.40M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Humacyte is $11.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy